Ketotifen (fumarate)

Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention[1][2][3][4].

Product Specifications

CAS Number

[34580-14-8]

Product Name Alternative

HC 20511 fumarate

UNSPSC

12352005

Hazard Statement

H302

Target

Endogenous Metabolite; Histamine Receptor; Influenza Virus; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Ketotifen-fumarate.html

Concentration

10mM

Purity

99.88

Solubility

DMSO : ≥ 100 mg/mL|H2O : 16.67 mg/mL (ultrasonic)

Smiles

O=C(C1=C/2C=CS1)CC3=CC=CC=C3C2=C4CCN(C)CC/4.O=C(O)/C=C/C(O)=O

Molecular Formula

C23H23NO5S

Molecular Weight

425.50

Precautions

H302

References & Citations

[1]Klooker TK, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010 Sep;59 (9) :1213-21.|[2]Zhang H, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020;35 (1) :1322-1330.|[3]Kiani P, et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021 Mar 26;13 (4) :558.|[4]Enkirch T, et al. Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity. Front Immunol. 2019 Jun 5;10:1097.|[5]Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17 (1) :218-234.